| __timestamp | Alnylam Pharmaceuticals, Inc. | CRISPR Therapeutics AG |
|---|---|---|
| Wednesday, January 1, 2014 | 190249000 | 1513000 |
| Thursday, January 1, 2015 | 276495000 | 12573000 |
| Friday, January 1, 2016 | 382392000 | 42238000 |
| Sunday, January 1, 2017 | 390635000 | 69800000 |
| Monday, January 1, 2018 | 505420000 | 113773000 |
| Tuesday, January 1, 2019 | 655114000 | 179362000 |
| Wednesday, January 1, 2020 | 654819000 | 266946000 |
| Friday, January 1, 2021 | 792156000 | 438633000 |
| Saturday, January 1, 2022 | 883015000 | 461645000 |
| Sunday, January 1, 2023 | 1004415000 | 387332000 |
| Monday, January 1, 2024 | 1126232000 | 320653000 |
Data in motion
In the rapidly evolving biotech landscape, innovation is the lifeblood of progress. Over the past decade, Alnylam Pharmaceuticals and CRISPR Therapeutics have been at the forefront of this revolution, investing heavily in research and development (R&D) to pioneer groundbreaking therapies.
Since 2014, Alnylam has consistently increased its R&D spending, culminating in a 428% rise by 2023. This commitment underscores their dedication to advancing RNA interference therapies, a field they have dominated.
CRISPR Therapeutics, though starting with modest R&D investments, has seen a staggering 25,500% increase over the same period. This surge reflects their aggressive pursuit of gene-editing technologies, positioning them as a leader in the CRISPR space.
Both companies exemplify the relentless pursuit of innovation, each carving a unique path in the biotech industry.
Analyzing R&D Budgets: AbbVie Inc. vs CRISPR Therapeutics AG
Research and Development Expenses Breakdown: Regeneron Pharmaceuticals, Inc. vs Alnylam Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and United Therapeutics Corporation
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and Incyte Corporation
Research and Development: Comparing Key Metrics for Alnylam Pharmaceuticals, Inc. and Exelixis, Inc.
Comparing Innovation Spending: Alnylam Pharmaceuticals, Inc. and Opthea Limited
Comparing Innovation Spending: Alnylam Pharmaceuticals, Inc. and Xencor, Inc.
Genmab A/S vs CRISPR Therapeutics AG: Strategic Focus on R&D Spending
Halozyme Therapeutics, Inc. vs CRISPR Therapeutics AG: Strategic Focus on R&D Spending
Amneal Pharmaceuticals, Inc. vs CRISPR Therapeutics AG: Strategic Focus on R&D Spending
R&D Spending Showdown: Apellis Pharmaceuticals, Inc. vs CRISPR Therapeutics AG
CRISPR Therapeutics AG or PTC Therapeutics, Inc.: Who Invests More in Innovation?